HelpAcademyLoginJoin us as a Member

GLAUKOS Corp

Sign in to save GLAUKOS Corp to a watchlist Sign in to set an alert for GLAUKOS CorpCompare GLAUKOS Corp with other companies
Tickers
GKOS
Headquarters
Not recorded
SEC CIK
0001192448
Website
Not recorded

Closing prices

Latest close, 246.03

Closing prices for GKOS251 stored closes for GKOS from 13 Nov 2025 to 12 Nov 2026. Lowest 88.40 on 17 Nov 2025, highest 247.16 on 11 Nov 2026, latest 246.03 on 12 Nov 2026.Close50.00100.00150.00200.00250.0013 Nov 202514 May 202612 Nov 2026
251 stored closes, oldest first. End of day, not intraday.

Source: Massive Closing prices as of End-of-day prices, not live

Massive Basic, non-business use; display licence needed before launch (D-1). Marketstack is kept as the backup source.

Not investment advice. End-of-day closing prices, not live quotes.

Drugs

Drugs from GLAUKOS Corp
DrugIndicationsPhaseNext catalystCT-VCATrials
Timolol eyeNot yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save Timolol eye to a watchlist GlaucomaPhase 3None scheduledNo published CT-VCA score1

FDA-approved applications

Drugs@FDA applications whose sponsor matches GLAUKOS Corp, newest first approval first
ApplicationBrand namesActive ingredientsFirst approvedStatus
NDA 219910EPIOXA HD/EPIOXA KITRIBOFLAVIN 5'-PHOSPHATE SODIUMPrescription
NDA 218010IDOSE TRTRAVOPROSTPrescription
NDA 203324PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA; PHOTREXA VISCOUS IN DEXTRAN 20%RIBOFLAVIN 5'-PHOSPHATE SODIUM; RIBOFLAVIN 5'-PHOSPHATEPrescription
NDA 022572MITOSOLMITOMYCINPrescription

Open in the approved-drug database for GLAUKOS Corp

Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.

Catalysts

No catalysts yet. Editors add each date together with its source.

Deals

No approved deals involve this company yet.

Reported fundamentals (SEC XBRL)

Latest value of each metric as reported to the SEC
MetricReported valuePeriodFiling
Revenue211,030,000 USD 1 Jul 2026 to 30 Sep 2026 FY2026 Q310-Q for Revenue on sec.gov (opens in a new tab)Filed
Net income (loss)2,018,000 USD 1 Jul 2026 to 30 Sep 2026 FY2026 Q310-Q for Net income (loss) on sec.gov (opens in a new tab)Filed
Research and development expense30,953,000 USD 1 Jul 2026 to 30 Sep 2026 FY2026 Q310-Q for Research and development expense on sec.gov (opens in a new tab)Filed
Operating expenses179,038,000 USD 1 Jul 2026 to 30 Sep 2026 FY2026 Q310-Q for Operating expenses on sec.gov (opens in a new tab)Filed
Cash and cash equivalents162,327,000 USD At 30 Sep 2026 FY2026 Q310-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed
Short-term investments and marketable securitiesNot reported in XBRL filings since 2015
Total liabilities262,255,000 USD At 30 Sep 2026 FY2026 Q310-Q for Total liabilities on sec.gov (opens in a new tab)Filed
Stockholders' equity717,274,000 USD At 30 Sep 2026 FY2026 Q310-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed
Common shares outstanding (cover page)59,196,870 shares At 26 Oct 2026 FY2026 Q310-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed

History

Revenue, newest period first
PeriodReported valueFiling
1 Jul 2026 to 30 Sep 2026 FY2026 Q3211,030,000 USD10-Q filed 28 Oct 2026 on sec.gov (opens in a new tab)Filed
1 Apr 2026 to 30 Jun 2026 FY2026 Q2185,610,000 USD10-Q filed 29 Jul 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2026 to 31 Mar 2026 FY2026 Q1150,571,000 USD10-Q filed 30 Apr 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Dec 2025 FY2025507,442,000 USD10-K filed 23 Feb 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2025 to 30 Sep 2025 FY2026 Q3133,537,000 USD10-Q filed 28 Oct 2026 on sec.gov (opens in a new tab)Filed
1 Apr 2025 to 30 Jun 2025 FY2026 Q2124,120,000 USD10-Q filed 29 Jul 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Mar 2025 FY2026 Q1106,664,000 USD10-Q filed 30 Apr 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2024 to 31 Dec 2024 FY2025383,481,000 USD10-K filed 23 Feb 2026 on sec.gov (opens in a new tab)Filed

The newest 12 periods of each metric are listed; older ones are on sec.gov.

Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.

Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-29 · read

SEC filings

SEC filings from GLAUKOS Corp, newest first
FormFiledWhat it coversDocument
8-K Current report (8-K) View Current report (8-K) filed 6 Nov 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-450710 (opens in a new tab)
4 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 5 Nov 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-450384 (opens in a new tab)
4 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 3 Nov 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-445961 (opens in a new tab)
4 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 3 Nov 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-445949 (opens in a new tab)
4 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 3 Nov 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-445902 (opens in a new tab)
8-K Current report (8-K) View Current report (8-K) filed 28 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-436147 (opens in a new tab)
10-Q Quarterly report (10-Q) View Quarterly report (10-Q) filed 28 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-436400 (opens in a new tab)
4Event 5 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 7 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001193125-26-417151 (opens in a new tab)
4Event 25 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 28 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001920053-26-000030 (opens in a new tab)
4Event 16 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 18 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001920053-26-000028 (opens in a new tab)

Source: SEC EDGAR. Each row links to the filing on sec.gov.

Related news

No recent headlines mention this company.

Insider transactions

All rows for GLAUKOS Corp on Insider Trades

Last 90 days of Form 4 filings, from 15 Aug 2026 (US Eastern dates).

Buys code P
None in this period
Sells code S
15 transactions, 19,316 shares, $3,450,466.40
Other all other codes
1 transaction: grants, exercises, tax withholding, gifts and similar

Last transaction:

Insider filings are public records and are not a recommendation. Source: SEC EDGAR.

Sources

Nothing on this page is investment advice.